Bioxodes

Executive Summary

Bioxodes is a Belgian clinical-stage biopharmaceutical company focused on developing first-in-class therapeutics for thrombo-inflammatory diseases. Its lead candidate, BIOX-101 (Ir-CPI), is designed to prevent thrombosis and neuroinflammation in hemorrhagic stroke patients by inhibiting neutrophil activation and coagulation factors without increasing bleeding risk. This unique mechanism addresses a critical unmet need, as current anticoagulants carry significant bleeding risks, especially in stroke patients. The company has completed Phase 1 studies demonstrating safety and tolerability, and is now advancing into Phase 2 trials. Bioxodes' approach could provide a safer alternative for managing thrombosis in high-risk populations, potentially transforming standard of care for hemorrhagic stroke.

Upcoming Catalysts (preview)

• Q4 2026Phase 2a interim data readout for BIOX-101 in hemorrhagic stroke60% success
• Q2 2026Regulatory milestone (e.g., FDA Fast Track or Orphan Drug designation)50% success
• Q3 2026Potential strategic partnership or licensing deal for BIOX-10140% success